March2026

OB-GYN

MEMORY DECLINE AFTER MENOPAUSE LINKED TO LOSS OF BRAIN-DERIVED ESTROGEN

Featuring: Serdar Bulun, MD, Hong Zhao, MD, PhD

​Preclinical findings identify extracellular matrix disruption as a potential mechanism contributing to increased Alzheimer’s disease risk in women

Key Findings
  • Sex-specific vulnerability: Females, but not males, demonstrate increased sensitivity to loss of brain-derived estrogen with aging
  • Novel mechanism: Estrogen depletion is associated with alterations in the hippocampal extracellular matrix (ECM)
  • Functional impact: ECM disruption may impair synaptic communication, memory and affective regulation
  • Therapeutic implication: Restoring ECM integrity may represent a preventive strategy prior to onset of cognitive decline
  • Clinical relevance: Provides mechanistic insight into why women account for nearly two-thirds of Alzheimer’s disease (AD) cases

A growing body of evidence has linked menopause-associated estrogen decline to increased risk of Alzheimer’s disease, yet the underlying biological mechanisms have remained incompletely understood. A new preclinical study published May 26, 2026, in Aging Cell provides important mechanistic insight, implicating disruption of the hippocampal extracellular matrix as a key mediator of estrogen-related cognitive decline in aging females.

The study, conducted by investigators at Northwestern University Feinberg School of Medicine, suggests that loss of brain-derived estrogen disproportionately affects females, altering structural components essential for synaptic function and memory. These findings may help explain the longstanding observation that nearly two-thirds of patients with Alzheimer’s disease are women.
 
A shift in focus: The extracellular matrix
Most neurodegenerative research has centered on neurons, glial cells and proteinopathies such as amyloid and tau. In contrast, this study highlights the importance of the extracellular matrix, a molecular scaffold occupying approximately 20 percent of brain volume. The extracellular matrix (ECM) plays a central role in maintaining synaptic architecture, facilitating cellular communication and supporting neuroplasticity, particularly in the hippocampus.

Using genetically engineered murine models with either global or brain-specific aromatase deficiency, investigators were able to isolate the effects of estrogen depletion. Across behavioral and molecular endpoints, aging female mice demonstrated pronounced susceptibility to ECM dysregulation in the setting of estrogen loss. This pattern was not observed in male mice.

“This study tells us that females — but not males — may be uniquely sensitive to loss of brain estrogen at old age, potentially contributing to an increased risk of Alzheimer’s disease,” said corresponding author Hong Zhao, MD, PhD, research professor of obstetrics and gynecology in the division of Reproductive Science in Medicine at Northwestern University Feinberg School of Medicine.
 
Estrogen and brain integrity
The findings reinforce the concept that estrogen is a critical neuromodulator with structural and functional roles in the central nervous system. Prior to menopause, ovarian production is the primary source of estrogen. Following menopause, systemic levels decline sharply, and only limited local production persists in extragonadal tissues, including the brain, adipose tissue, bone, muscle, vasculature and breast tissue.

In this model, female mice relied predominantly on locally synthesized brain estrogen, making them particularly vulnerable to its loss. This is consistent with prior research demonstrating that women with Alzheimer’s disease may have lower levels of brain estrogen compared with cognitively normal women.

At the molecular level, estrogen depletion in aged females was associated with altered gene expression in the hippocampus, particularly in genes regulating ECM structure and organization. These changes were accompanied by impairments in memory, affective behavior and social function.

“We have provided some of the most compelling evidence that estrogen is so important for memory function and other mood functions in the female brain,” says senior author Serdar Bulun, MD, chair of the department of Obstetrics and Gynecology at Feinberg and a Northwestern Medicine physician.

“This should motivate clinicians to be more aware of the essential role of estrogen for women’s brains, because once memory is gone, it’s gone.”
 
Implications for Alzheimer’s disease pathophysiology
The study introduces ECM disruption as a previously underrecognized contributor to neurodegeneration, particularly in sex-specific aging. Rather than focusing exclusively on neuronal injury or amyloid deposition, the findings suggest that the neurostructural microenvironment itself may represent an early and modifiable component of disease progression.

Current anti-amyloid therapies, including lecanemab and donanemab, can reduce amyloid burden but have demonstrated variable and often modest clinical benefit in slowing cognitive decline or improving functional outcomes. These limitations highlight the need for complementary therapeutic targets.

Targeting ECM integrity may represent one such approach. By preserving the structural framework necessary for neuronal communication, interventions aimed at maintaining or restoring the ECM could potentially delay or mitigate cognitive decline before irreversible neuronal loss occurs.
 
Reconsidering hormone therapy
The findings also add biological context to ongoing questions surrounding hormone replacement therapy (HRT). Clinical studies evaluating HRT for cognitive protection have produced mixed results, with outcomes influenced by timing of initiation, formulation and study design.

These data support the hypothesis that preservation of estrogen signaling, particularly within the brain, may be time-sensitive. They also suggest that estrogen’s neuroprotective effects may be mediated in part through maintenance of ECM structure rather than through direct neuronal effects alone.

“More research is needed to understand how estrogen affects the female brain and why estrogen loss increases Alzheimer’s disease risk in women,” Zhao says. “Understanding these mechanisms could help researchers develop safer and more effective HRT strategies to prevent or slow the progression of Alzheimer’s disease in women.”
 
Clinical relevance for OB/GYN and geriatric practice
For clinicians in obstetrics and gynecology, as well as geriatric medicine, these findings underscore the importance of considering menopause as a neurologically significant transition. Estrogen decline may have structural consequences within the brain that influence long-term cognitive health.

The study supports:
  • Greater attention to cognitive risk assessment in postmenopausal patients
  • Recognition of sex-specific neurobiological aging pathways
  • Continued evaluation of timing and formulation of HRT
  • Exploration of emerging therapies targeting the brain microenvironment
 
Conclusion
This study provides compelling preclinical evidence linking loss of brain-derived estrogen to extracellular matrix disruption and cognitive decline in aging females. By identifying a novel and potentially modifiable pathway, it advances understanding of sex disparities in Alzheimer’s disease and opens new avenues for prevention and treatment.

As the burden of dementia continues to grow, integrating neuroendocrine mechanisms into clinical research and care will be essential, particularly for postmenopausal women at increased risk.

See the full publication.
See press coverage on Inc.  
Serdar Bulun, MD, chair of the department of Obstetrics and Gynecology at Feinberg and a Northwestern Medicine physician.
Hong Zhao, MD, PhD, research professor of obstetrics and gynecology in the division of Reproductive Science in Medicine at Northwestern University Feinberg School of Medicine.

Refer a Patient

Northwestern Medicine welcomes the opportunity to collaborate with you in caring for your patients. ​

You May Also Like